Raised to Date: Raised: $23,191
Total Commitments ($USD)
Equity - Common
Rolling Commitments ($USD)
Right now, Tumor Treating Fields (TTF) is a therapy found very successful in helping us win that battle against solid tumor cancer However, that is only true for when patients have one solid tumor cancer. When a late-stage cancer patients presents with metastatic disease in two or more locations on the body at once, TTF cannot treat both of those areas at once. The patient must make the painful decision of which cancer to treat...and which cancer to let grow.
That’s where Lifebridge 10,000 comes into play and as the anti-cancer, pro-TTF white knight. Inspired by Laurie, CEO Peter Travers’ wife, Lifebridge 10,000 has built and successfully tested a patent-pending prototype that would allow TTF to treat multiple cancers at once in that type of situation. Laurie was forced to make the choice of which cancer to fight and which cancer to leave, and Peter wants to make sure that cancer patients using TTF will not have to make that decision ever again.
A percentage of profits will be given to patients who cannot afford treatment. LifeBridge will also sell their therapy on a sliding scale, with those less fortunate given significant discounts. Sadly, the market for this device is strong, and the demand is high. WHO predicts a 65% growth in the number of new cancer patients over the next 15 years, and pharmaceutical companies are jumping on board with TTF - Pfizer, Johnson and Johnson, and other firms have raised over $250,000,000 to make TTF the accepted 4th modality for cancer treatment.
The bottom line is that investing in Lifebridge 10,000 could mean that you’ll get a doubly high return - your profit means that you’re helping to beat cancer.
Upgrade to gain access
- Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- , plus
- Company specific
- Advanced company search ( )
- Get Edge Annual
- Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- In-depth risk ratings for every raise
- Get Edge Pro Annual